New drugs: methylnaltrexone bromide, alvimopan, and rilonacept

J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):688-91. doi: 10.1331/JAPhA.2008.08537.
No abstract available

MeSH terms

  • Analgesics, Opioid / adverse effects
  • Carrier Proteins / genetics
  • Constipation / chemically induced
  • Constipation / drug therapy
  • Familial Mediterranean Fever / drug therapy
  • Familial Mediterranean Fever / genetics
  • Humans
  • Ileus / drug therapy
  • Ileus / etiology
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • Naltrexone / administration & dosage
  • Naltrexone / analogs & derivatives*
  • Narcotic Antagonists / administration & dosage
  • Piperidines / administration & dosage*
  • Postoperative Complications / drug therapy
  • Postoperative Complications / etiology
  • Quaternary Ammonium Compounds / administration & dosage
  • Recombinant Fusion Proteins / administration & dosage*
  • Syndrome

Substances

  • Analgesics, Opioid
  • Carrier Proteins
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Narcotic Antagonists
  • Piperidines
  • Quaternary Ammonium Compounds
  • Recombinant Fusion Proteins
  • methylnaltrexone
  • Naltrexone
  • alvimopan
  • rilonacept